Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

This is a "first in human" study to determine the safety and tolerability of the drug after single doses. Nine doses of increasing strength will be injected or infused (given into a vein) to 9 different groups of people. One third of the participants will be given an injection or infusion of placebo (sugar water). All participants will be healthy people.

Key facts

Study ID

NCT01162889

Run by

Pfizer

People needed

70

Starts

2010-06-01

Expected to finish

2012-01-01

Last updated by the study team

2012-03-15

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Females of non-childbearing potential
• Body mass index between 17.5 to 30.5 and body weight > 50 kg

You may not qualify if…

• History of significant medical illness
• Positive urine drug screen or alcohol dependance
• Smoking > 10 cigarettes per day

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.